A national, prospective single arm phase II study investigating the pharmacokinetics and safety of the 2% TD1414 cream when applied 3 times daily for 7 days to adult patients with impetigo or Secondarily Infected Traumatic Lesions (SITL). A total of 20 patients will be enrolled.

Start Date01 Dec 2008

Sponsor / Collaborator

Leo Pharma, Inc.

NCT00626795

/ CompletedPhase 2

Efficacy, Safety and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)

An international, multi-centre, prospective three arm parallel-group, phase II proof of concept study comparing the efficacy and safety of two dosage regimens (BID 7 days and TID 7 days) of TD1414 2% cream and one dosage regimen (BID 7 days) of Bactroban® (mupirocin) 2% cream in adults and children down to 2 years of age with impetigo or SITL. Furthermore an evaluation of the pharmacokinetics of TD1414 2% cream TID for 7 days will be performed. A total of 664 patients will be enrolled in a stepwise manner according to age groups starting with the oldest age group.

Start Date01 Feb 2008

Sponsor / Collaborator

Leo Pharma, Inc.

100 Clinical Results associated with TD-1414

100 Translational Medicine associated with TD-1414

100 Patents (Medical) associated with TD-1414

Literatures (Medical) associated with TD-1414

Nature CommunicationsQ1 · CROSS-FIELD

Transport of lipophilic carboxylates is mediated by transmembrane helix 2 in multidrug transporter AcrB

Q1 · CROSS-FIELD

ArticleOA

Author: Tam, Heng-Keat ; Oswald, Christine ; Pos, Klaas M

AbstractThe deployment of multidrug efflux pumps is a powerful defence mechanism for Gram-negative bacterial cells when exposed to antimicrobial agents. The major multidrug efflux transport system in Escherichia coli, AcrAB–TolC, is a tripartite system using the proton-motive force as an energy source. The polyspecific substrate-binding module AcrB uses various pathways to sequester drugs from the periplasm and outer leaflet of the inner membrane. Here we report the asymmetric AcrB structure in complex with fusidic acid at a resolution of 2.5 Å and mutational analysis of the putative fusidic acid binding site at the transmembrane domain. A groove shaped by the interface between transmembrane helix 1 (TM1) and TM2 specifically binds fusidic acid and other lipophilic carboxylated drugs. We propose that these bound drugs are actively displaced by an upward movement of TM2 towards the AcrB periplasmic porter domain in response to protonation events in the transmembrane domain.

100 Deals associated with TD-1414

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bites, Human	Phase 2	United States	Leo Pharma, Inc.	01 Dec 2008
Burns	Phase 2	United States	Leo Pharma, Inc.	01 Dec 2008
Impetigo	Phase 2	South Africa	Leo Pharma, Inc.	01 Feb 2008
Impetigo	Phase 2	United States	Leo Pharma, Inc.	01 Feb 2008
Wounds and Injuries	Phase 2	South Africa	Leo Pharma, Inc.	01 Feb 2008
Complicated skin and soft tissue infection	Phase 2	United States	LEO Pharma A/S	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00758862 (CTgov)	Phase 2	Burns \| Impetigo \| Wounds and Injuries \| Bites, Human	20	TD1414	vmtkmafvbo(xwffzqfyyr) = maysuakofh cvfgpsyaqn (emvcvdipop, ydgdbwzkha - dqnlrznyvo) View more	-	23 Jul 2018
NCT00626795 (CTgov)	Phase 2	Impetigo \| Wounds and Injuries	773	TD1414 (TD1414 BID)	(gcmfauyutj) = pvnvnaibih cwnyfufhsg (yhubppcksk, jbrlxtodfx - hbnoarlmqn) View more	-	23 Jul 2018
NCT00626795 (CTgov)	Phase 2	Impetigo \| Wounds and Injuries	773	TD1414 (TD1414 TID)	(gcmfauyutj) = exgmscmovh cwnyfufhsg (yhubppcksk, ttpnfffxui - pmujffndmw) View more	-	23 Jul 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

TD-1414

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation